Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain MYOK message board posts where the ticker symbol MYOK has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest MYOK SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-021742 Size: 14 KB
2018-08-08
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001564590-18-020521 (34 Act)  Size: 7 MB
2018-08-08 001-37609
181001815
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001564590-18-020475 (34 Act)  Size: 284 KB
2018-08-08 001-37609
181001491
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-020579 Size: 15 KB
2018-07-25
SC 13G  Documents Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001144204-18-038333 (34 Act)  Size: 166 KB
2018-07-13 005-89169
18952553
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-019546 Size: 16 KB
2018-07-06
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-018747 Size: 10 KB
2018-06-29
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-018746 Size: 10 KB
2018-06-29
8-K  Documents Current report, item 5.07
Acc-no: 0001193125-18-194484 (34 Act)  Size: 18 KB
2018-06-15 001-37609
18902279
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-016601 Size: 5 KB
2018-06-14
More MYOK SEC Filings


Related news from
Thu, 09 Aug 2018
00:05:12 +0000
MyoKardia (MYOK) Reports Q2 Loss, Tops Revenue Estimates
MyoKardia (MYOK) delivered earnings and revenue surprises of 2.00% and 5.13%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Wed, 08 Aug 2018
23:02:39 +0000
MyoKardia: 2Q Earnings Snapshot
The South San Francisco, California-based company said it had a loss of 49 cents per share. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Wed, 08 Aug 2018
20:02:00 +0000
MyoKardia Reports Second Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2018-- MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today reported financial ...
Wed, 08 Aug 2018
19:10:02 +0000
Backed with $140M, startup launches three-pronged attack on liver diseases
Startup factory Third Rock Ventures is launching a three-pronged attack on liver diseases with $140 million and an unusually early and large assist from a Japanese drug maker.
Wed, 08 Aug 2018
18:30:00 +0000
MyoKardia, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / MyoKardia, Inc. (NASDAQ: MYOK ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30:00 PM Eastern Time. ...
Tue, 07 Aug 2018
20:01:00 +0000
MyoKardia to Present at the 2018 Wedbush Pacgrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2018-- MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, ...
Wed, 01 Aug 2018
20:30:00 +0000
MyoKardia to Report Second Quarter 2018 Financial Results on Wednesday, August 8, 2018
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2018-- MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, ...
Wed, 25 Jul 2018
11:40:00 +0000
Breakfast Technical Briefing on Neptune Technologies & Bioressources and Three Other Additional Biotech Stocks
LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want a free Stock Review on NEPT sign up now at www.wallstequities.com/registration. Under evaluation this morning are the following equities: Magenta Therapeutics Inc. (MGTA), Matinas BioPharma Holdings Inc. (NYSE AMER: MTNB), MyoKardia Inc. (NASDAQ: MYOK), and Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT).
Tue, 10 Jul 2018
18:06:10 +0000
BofA Revives Myokardia With New Buy Rating
Myokardia Inc (NASDAQ: MYOK ) stock is up 290 percent year-over-year, but upcoming stimulants could drive additional outperformance, according to Bank of America Merrill Lynch.  The Analyst BofA's  Tazeen ...
Tue, 03 Jul 2018
12:10:00 +0000
Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and MyoKardia
NEW YORK, NY / ACCESSWIRE / July 3, 2018 / U.S. equities closed up on Monday, supported by a rally from the technology sector. However, growing trade concerns continue to weigh on the markets. The Dow ...
Tue, 26 Jun 2018
12:30:00 +0000
MyoKardia Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy
MyoKardia, Inc. (MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that the first patient has been dosed in the company’s Phase 3 EXPLORER-HCM clinical trial.  The pivotal study is intended to evaluate the efficacy and safety of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM).  MyoKardia expects to report data from the Phase 3 trial in the second half of 2020. EXPLORER-HCM is a multi-national randomized double-blind study that will enroll approximately 220 patients with symptomatic oHCM.  Patients will be randomized on a 1:1 basis to receive either mavacamten or placebo for a 30-week treatment period.  The EXPLORER-HCM trial design incorporates individualized dosing, including two dose adjustments during the 30-week treatment period based on measurements of provoked left ventricular outflow tract (LVOT) gradient.  All assessments and dose adjustments will be conducted in a double-blinded fashion.  Patients will be allowed to maintain their HCM-related background medications for the duration of the EXPLORER-HCM Phase 3 trial, including beta blockers or calcium channel blockers.  An independent data monitoring committee (IDMC) has been established to monitor safety throughout the study.
Wed, 06 Jun 2018
12:30:00 +0000
Analysis: Positioning to Benefit within Willis Towers Watson Public, MyoKardia, Texas Capital Bancshares, uniQure N.V, Retail Opportunity Investments, and GDS Holdings Limited — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, June 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Willis ...
Wed, 23 May 2018
00:05:00 +0000
MyoKardia Announces Pricing of Public Offering of Common Stock
MyoKardia, Inc. (MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the pricing of an underwritten public offering of 3,750,000 shares of its common stock at a public offering price of $49.00 per share, before underwriting discounts. MyoKardia anticipates using the net proceeds from the offering, together with its existing cash, cash equivalents and short-term and long-term investments, to fund research and development activities for its development programs, including, but not limited to, its planned Phase 3 EXPLORER-HCM clinical trial of mavacamten and its planned Phase 2 clinical trial of MYK-491, as well as its other ongoing and planned clinical trials for mavacamten and MYK-491, its ongoing preclinical, discovery and research programs and the expansion of its platform, and for working capital and other general corporate purposes.
Mon, 21 May 2018
20:01:00 +0000
MyoKardia Announces Proposed Public Offering of Common Stock
MyoKardia, Inc. (MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it has commenced a proposed underwritten public offering of 3,750,000 shares of its common stock. All shares of common stock will be offered by MyoKardia. In addition, MyoKardia expects to grant the underwriters a 30-day option to purchase an additional 562,500 shares of common stock at the public offering price, less the underwriting discount.
Mon, 21 May 2018
11:30:00 +0000
MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
Single Pivotal to Support Registration; Target Enrollment of 220 Patients; Primary Endpoint of Clinical Response Using Peak VO 2 and NYHA Classification Improvements. Expected to Initiate in Second Quarter ...
Fri, 18 May 2018
23:07:09 +0000
Should You Buy MyoKardia Inc (NASDAQ:MYOK) At $50.55?
MyoKardia Inc (NASDAQ:MYOK), a pharmaceuticals company based in United States, saw a double-digit share price rise of over 10% in the past couple of months on the NasdaqGS. As aRead More...
Wed, 09 May 2018
18:35:26 +0000
Edited Transcript of MYOK earnings conference call or presentation 8-May-18 8:30pm GMT
Q1 2018 MyoKardia Inc Earnings Call



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "VF is an awesome community of bright, serious, passionate and involved individual investors. Information is well organized into fine-grained topics and discussions are always on topic and relevant. People here certainly know what value is and this site itself is a great reflection of that. I feel honored and privileged to have found such a great resource and to be part of it!" more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards